Nuformix (LON:NFX) Stock Price Down 1.6% – Should You Sell?

Nuformix plc (LON:NFX) fell 1.6% on Wednesday . The company traded as low as GBX 0.06 ($0.00) and last traded at GBX 0.06 ($0.00). 13,051,383 shares were traded during mid-day trading, an increase of 124% from the average session volume of 5,828,061 shares. The stock had previously closed at GBX 0.06 ($0.00).

Nuformix Stock Up 7.1 %

The company has a quick ratio of 3.35, a current ratio of 1.12 and a debt-to-equity ratio of 1.17. The business has a 50-day simple moving average of GBX 0.13 and a 200-day simple moving average of GBX 0.17. The company has a market cap of £491,586.00, a PE ratio of -1.63 and a beta of 1.22.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.